Abnova, founded in Year 2002 and held its Initial Public Offering (IPO) in Taiwan in Year 2009, is the first biotech company success-fully integrated the IT-style management and industrial-scale antibody manufacturing. It is also the world's largest antibody manufacturer. Rather than the traditional method of antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. In